基于MRI的深度学习评估阿尔茨海默病谱系中淀粉样蛋白、tau蛋白和神经退行性变生物标志物状态
本研究回顾性收集阿尔茨海默病影像学倡议的MRI与PET配对数据(淀粉样蛋白2099对、tau蛋白557对、FDG PET 2768对),利用卷积神经网络提取MRI特征并结合人口学、APOE基因状态、认知评分、海马体积和临床诊断,预测PET确定的ATN生物标志物状态。测试集AUC分别为淀粉样蛋白0.79、tau蛋白0.73、神经退行性变0.86,表明该深度学习算法具有可接受至优秀的预测效能。
要点
- MRI联合常规诊断数据可无创预测PET确定的ATN生物标志物状态,测试集AUC为淀粉样蛋白0.79、tau蛋白0.73、神经退行性变0.86。
- 模型高梯度区域位于颞叶、顶叶、额叶和枕叶关键皮质区,认知评分、海马体积和APOE状态的模型系数最高。
- 该算法为ATN分类提供了非侵入性替代思路,但tau蛋白模型AUC的95%CI较宽(0.58, 0.86)。
核心结论
- 深度学习算法利用MRI及其他可用诊断数据预测PET确定的ATN状态各组分,效能为可接受至优秀。
研究设计与样本
- 回顾性研究,数据来自阿尔茨海默病影像学倡议,PET与30天内MRI配对(2005年8月至2020年9月),按70%训练、10%验证、20%最终测试随机划分;采用双峰高斯混合模型将PET阈值化为阳性和阴性标签;卷积神经网络提取MRI特征,结合人口学、APOE基因状态、认知评分、海马体积和临床诊断的逻辑回归模型分类各ATN组分;以AUC评价模型。样本量:淀粉样蛋白2099对(平均年龄75岁±10,男性1110例)、tau蛋白557对(平均年龄75岁±7,男性280例)、FDG PET 2768对(平均年龄75岁±7,男性1645例)。
关键影像表现/征象
- 网络内高梯度存在于颞叶、顶叶、额叶和枕叶关键皮质区域。
- 认知评分、海马体积和APOE状态的模型系数最高。
诊断标准与关键数值
- 淀粉样蛋白测试集AUC为0.79(95%CI: 0.74, 0.83)。
- tau蛋白测试集AUC为0.73(95%CI: 0.58, 0.86)。
- 神经退行性变测试集AUC为0.86(95%CI: 0.83, 0.89)。
临床应用与阅片要点
- 模型输出可用于辅助判断PET确定的ATN各组分阳性和阴性状态,但需注意tau蛋白AUC的95%CI较宽。
- 阅片时可关注颞叶、顶叶、额叶和枕叶皮质区域,这些区域在模型中梯度较高。
- 认知评分、海马体积和APOE状态对模型贡献最大,报告时可结合这些信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background PET can be used for amyloid-tau-neurodegeneration (ATN) classification in Alzheimer disease, but incurs considerable cost and exposure to ionizing radiation. MRI currently has limited use in characterizing ATN status. Deep learning techniques can detect complex patterns in MRI data and have potential for noninvasive characterization of ATN status. Purpose To use deep learning to predict PET-determined ATN biomarker status using MRI and readily available diagnostic data. Materials and Methods MRI and PET data were retrospectively collected from the Alzheimer's Disease Imaging Initiative. PET scans were paired with MRI scans acquired within 30 days, from August 2005 to September 2020. Pairs were randomly split into subsets as follows: 70% for training, 10% for validation, and 20% for final testing. A bimodal Gaussian mixture model was used to threshold PET scans into positive and negative labels. MRI data were fed into a convolutional neural network to generate imaging features. These features were combined in a logistic regression model with patient demographics, APOE gene status, cognitive scores, hippocampal volumes, and clinical diagnoses to classify each ATN biomarker component as positive or negative. Area under the receiver operating characteristic curve (AUC) analysis was used for model evaluation. Feature importance was derived from model coefficients and gradients. Results There were 2099 amyloid (mean patient age, 75 years ± 10 [SD]; 1110 male), 557 tau (mean patient age, 75 years ± 7; 280 male), and 2768 FDG PET (mean patient age, 75 years ± 7; 1645 male) and MRI pairs. Model AUCs for the test set were as follows: amyloid, 0.79 (95% CI: 0.74, 0.83); tau, 0.73 (95% CI: 0.58, 0.86); and neurodegeneration, 0.86 (95% CI: 0.83, 0.89). Within the networks, high gradients were present in key temporal, parietal, frontal, and occipital cortical regions. Model coefficients for cognitive scores, hippocampal volumes, and APOE status were highest. Conclusion A deep learning algorithm predicted each component of PET-determined ATN status with acceptable to excellent efficacy using MRI and other available diagnostic data. © RSNA, 2023 Supplemental material is available for this article.
引用
- Lew CO, Zhou L, Mazurowski MA, et al. MRI-based Deep Learning Assessment of Amyloid, Tau, and Neurodegeneration Biomarker Status across the Alzheimer Disease Spectrum. Radiology. 2023. PMID: 37815445. doi:10.1148/radiol.222441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。